Boston Therapeutics Announces New COO, Loraine V. Upham
9:01 am ET February 20, 2018 (Globe Newswire) Print
Boston Therapeutics, Inc. announces that Loraine V. Upham will join the team to lead the US operations and drug development effort for the diabetes portfolio. Formerly of Eli Lilly and Merck and Company, Upham brings both large pharmaceutical experience and private development stage company experience to the Boston Therapeutics team.
"We are pleased to have Lori join the US team, allowing us to expand the Boston Therapeutics global foot print. Her energy and commitment to the development and commercial success of our metabolic, diabetes and prediabetes portfolio in the US and abroad will join our growing Asia market presence this coming year as we establish ourselves for partnering and expansion in the US," explains CEO, Carl Rausch. "Her experience and enthusiasm will fit with our global clinical plans as we commence clinical trials in the US. We can now leverage the China and Asia effort with the resources of a fully integrated global company."
Upham co-founded CureDM in 2004, raised private capital, formed partnerships and helped drive the HIP2B peptide product development from just an idea to its current Phase 2-ready status. "I am honored to be a part of the Boston Therapeutics team. It provides a platform for the development of our existing compounds and other novel treatments that fit the strategic profile of changing the global economic impact of diabetes and its costly complications. A recent report entitled, 'Economic Implications of Improving Type 2 Diabetes Management in China' really underscores the worldwide importance and opportunity to make a difference with innovations like ours."
Upham will report directly to CEO, Carl Rausch, and work closely with investment bank operations and US based partners to support operations in the US.
About Boston Therapeutics, Inc. www.bostonti.com
Boston Therapeutics, headquartered in Lawrence, MA (OTCQB:BTHE) is an innovator in design, development and commercialization of compounds to treat diabetes and diabetes related complications.
Forward Looking Statement
This press release includes forward-looking statements. These statements may be identified by words such as "feel," "believes," expects," "estimates," "projects," "intends," "should," "is to be," or the negative of such terms, or other comparable terminology. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein. Factors that could cause actual results to differ materially include, but are not limited to: our limited operations and need to expand in the near future; risks associated with obtaining regulatory approval of our products; the ability to protect our intellectual property; the potential lack of market acceptance of our products; potential competition; our inability to retain key members of our management team; our inability to raise additional capital to fund our operations and business plan; our ability to continue as a going concern; our liquidity and other risks and uncertainties and other factors discussed from time to time in our filings with the Securities and Exchange Commission ("SEC"), including our annual report on Form 10-K filed with the SEC. Boston Therapeutics expressly disclaims any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.
Contact: Boston Therapeutics, Inc.
Carl Rausch, CEO